San Diego-primarily based Viking Therapeutics marked alone as a serious competitor during the weight loss drug market place in February after revealing promising knowledge from a mid-phase trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when offered as being a weekly injection and in March the